We analyzed the mutational hotspot region of SRSF2 (Pro95) in 275 cases with CMML. In addition, ASXL1, CBL, EZH2, JAK2V617F, KRAS, NRAS, RUNX1, and TET2 mutations were investigated in subcohorts. Mutations in SRSF2 (SRSF2mut) were detected in 47% (129/275) of all cases. In detail, 120 cases had a missense mutation at Pro95 leading to a change to Pro95His, Pro95Leu, Pro95Arg, Pro95Ala, or Pro95Thr. In 9 cases, three new in/del mutations were observed: seven cases with a 24 bp deletion, one case with a 3 bp duplication, and one case with a 24 bp duplication. In silico analyses predicted a damaging character for the protein structure of SRSF2 for all mutations. SRSF2mut were correlated with higher age, less pronounced anemia and a normal karyotype. SRSF2mut and EZH2mut were mutually exclusive but SRSF2mut associated with TET2mut. In the total cohort, no impact of SRSF2mut on survival was observed. However in the RUNX1mut subcohort, SRSF2 Pro95His had a favorable impact on overall survival. This comprehensive mutation analysis revealed that 93% of all CMML patients carried at least one somatic mutation in 9 recurrently mutated genes. In conclusion, these data show the importance of SRSF2mut as new diagnostic marker in CMML.
Introduction
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy that can be characterized by features of both, a myelodysplastic syndrome (MDS) and a myeloproliferative neoplasm (MPN) . Therefore the WHO classification of 2008 assigned CMML to the mixed category MDS/MPN. 1 A further characteristic feature is the wide heterogeneity of clinical presentations and course, leading to variable prognosis. Beside cytological criteria for diagnosis, the only genetic criterion, until recently, was the absence of the BCR-ABL1 fusion transcript. The number of blasts in the peripheral blood (PB) and bone marrow (BM) is a prognostic factor dividing CMML cases into two morphological categories:
CMML-1 with fewer than 5% blasts in PB or 10% in BM, and CMML-2 with 5-19% blasts in PB or 10-19% in BM. 1 Median overall survival is about 20 months in CMML-1 and 15 months in CMML-2, but wide variations exist. 2 In approximately 15-30% of CMML patients, the disease evolves into acute myeloid leukemia (AML). 2.5x10 9 /L, peripheral blood IMCs more than 0%, and bone marrow blasts 10% or more. 3 The vast majority of patients show a normal karyotype in the CMML cells and only 20-40% show clonal cytogenetic abnormalities. 1 Such and coworkers investigated 414 patients with CMML to evaluate the prognostic impact of cytogenetic abnormalities and identified three risk categories. 4 A normal karyotype or loss of the Y-chromosome as a sole abnormality represent the low risk group; trisomy 8, abnormalities of chromosome 7 or a complex karyotype (defined as three or more abnormalities) were related to the high risk group. All other abnormalities were assigned to the intermediate risk category.
In contrast to cytogenetic aberrations, several molecular gene mutations recently have been found to be frequent in CMML (resulting in overall mutation frequencies of >55% [5] [6] [7] [8] ); but unfortunately, none of these alterations is specific for CMML. Gene mutations identified in CMML cases affect different cellular targets and processes, like RUNX1
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(transcriptional regulation), Isocitrate Dehydrogenases IDH1/2 10 (metabolism), or KRAS, NRAS, 11;12 CBL, 13 and JAK2 14 (tyrosine-signaling pathways). TET2, 15 DNMT3A, 16 ASXL1, 17 UTX, 18 and EZH2 19 contribute in the broadest sense to epigenetic regulatory mechanisms. All of the cytogenetic changes and molecular mutations have been associated with the pathogenesis of CMML but do not fully explain leukemogenesis.
Thus far, mutations in several of these genes already show prognostic relevance. To date, EZH2 is the best molecularly analyzed gene in CMML and implies an unfavorable prognosis. 5 Mutation of ASXL1 correlates with evolution to AML and a shorter overall Previously, we have investigated 81 CMML cases and analyzed the mutation frequency of a number of genes that were found to be recurrently mutated in CMML. These comprehensive studies resulted in an overall mutation frequency of 82%, 5;6 indicating that there is a certain percentage of patients with unknown molecular alterations.
More recently, an additional cellular process was found to be altered in MDS. A whole-exome sequencing approach of 29 MDS specimens and their normal controls detected mutations in several components of the splicing machinery (i.e. spliceosome; like SF3B1 and U2AF1), mostly involved in 3'-splice site recognition. In this context a new candidate gene, SRSF2 (serine/arginine-rich splicing factor 2, also known as SC35, a classical member of the SR-protein family), was identified in close cooperation with our laboratory. 7 Members of the SR-protein family function in constitutive and alternative splicing.
They contain a RNA recognition motif (RRM) for binding to RNA and a Arginine/Serine-rich (RS)-domain for interaction with other SR-proteins (Fig. 1) . As a component of the spliceosome, SRSF2 binds to exonic splicing enhancers preventing exon skipping and ensuring the correct linear order of exons in spliced mRNA. 25;26 In our recent study, mutations within the SRSF2 sequence occurred exclusively at position 95 (Pro95), located in a linker sequence between the two functional RRM-and RS-domains. SRSF2 was found to be most frequently mutated in CMML (28%), less frequently in MDS without increased ring sideroblasts (12%), and to some extent in refractory anemia with ring sideroblasts (RARS; 6%) and AML/MDS (7%). It was rarely seen to be mutated in MPN (2%) or de novo AML (1%).
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To characterize further the genetic defects of CMML, we analyzed the frequency of SRSF2 mutations, their coincidence with other mutations, and their prognostic relevance in a large cohort of 275 cases.
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Patients and Methods

Patient Cohort
In total, 275 cases with CMML were analyzed. All cases were validated on peripheral blood and/or bone marrow smears according to WHO standards 1 and included in all cases May
Grünwald Giemsa (MGG) staining, as well as myeloperoxidase (MPO), non-specific esterase (NSE), and iron stains. 27 The cohort comprised 189 males and 86 females with a median age of 72.8 years (range: 21.9 -93.3 years). 81 patients that have been published previously by our group except for SRSF2 entered the cohort. 5;6 There is no overlap with the CMML-cohort analyzed in Yoshida et al. 7 Cytogenetic analyses were performed after short-term culture.
Karyotypes were analyzed after G-banding and described according to the International System for Human Cytogenetic Nomenclature (ISCN 1995 guidelines). 28 Further parameters are given in Table 1 . All patients gave their consent for genetic analyses and the use of laboratory results for research purposes. The study design adhered to the tenets of the Declaration of Helsinki and was approved by our institutional review board before its initiation.
Sequencing Analyses
Isolation of mononuclear cells, DNA and mRNA extraction, as well as random primed cDNA synthesis was performed as described previously. 29 6 and TET2 (n=160). 6 The coding sequence of SF3B1 (n=171) was analyzed by Sanger sequencing. U2AF1 Ser34 and Gln157 (n=265) were analyzed by melting curve analyses. 
Characterization and frequency of SRSF2 mutations
To analyze the mutation frequency of SRSF2 in our CMML cohort of 275 patients (Table 1) , we investigated the sequence of an amplicon covering the mutation hotspot codon Pro95.
Alterations of Pro95 or adjacent sequences were detected in 47% (129/275) of all cases.
Mutation frequencies were similar in CMML-1 (47%; 91/193) and CMML-2 (46%; 38/82). In detail, 119 cases had a missense mutation leading to a change of Pro95 to one of the following five residues: p.Pro95His (n=56), p.Pro95Leu (n=38), p.Pro95Arg (n=23), p.Pro95Ala (n=1), p.Pro95Thr (n=1). In all cases, an estimated mutation load of 30-50% in accordance with a heterozygous mutation status was detected. Figure 1 gives a schematic overview of the protein organization (based on information given by UniProtKB Q01130) and the mutation type, localization and frequency.
SRSF2 mutated sequences are shown in Supplemental Figure S2A .
In silico analyses
In order to estimate the damaging character of these specific missense mutations at Pro95, proteins ( Figure 2A ).
The differences between these models were determined by calculating the Cα-Cα distances between the two corresponding AA of SRSF2wt and mutant SRSF2 for AA 88 to show that all calculated models very well fit the known crystal structure of the RRM-domain up to AA 92, and larger changes appear within the mutated linker sequences.
Taken together, the in silico analyses indicate that the linker sequence, particularly amino acid 95, likely has a relevant impact on protein structure.
Correlation of SRSF2 with karyotype
As shown before, the majority of patients had a normal The mutation frequencies and associations are shown in Table 1 and Fig. 3 , respectively.
Mutations in IDH1/2, U2AF1, and SF3B1 occurred in ≤ 5% of patients and are therefore depicted in Supplemental Figure S3 .
For
Analyses of coincidences showed that SRSF2 mutations were nearly mutually exclusive of EZH2 mutations. Of the 20 cases with an EZH2 mutation only one had a SRSF2 mutation. In counter-distinction, in the 208 cases with wt EZH2, SRSF2 was mutated in 106 samples (56%; p<0.001). In contrast, a high coincidence of SRSF2 mutations occurred with TET2 mutations as 62% (60/97) of the samples with TET2mut had a SRSF2 mutation; while in the TET2wt group, only 35% (22/63) also carried a mutation in SRSF2 (p=0.001). With respect to associations with all the other genes, no specific associations were observed (Fig.   3B) . In a further analysis the coincidences of SRSF2mut with any other gene mutation were analyzed separately for CMML-1 and CMML-2 cases. Both groups reflect the same associations as observed in the total cohort (Supplemental Figure S4 ).
Comprehensive analysis of gene mutations
In a subset of 148 cases of the cohort, the mutational status data of nine genes were
available (SRSF2, ASXL1, CBL, EZH2, JAK2, KRAS, NRAS, RUNX1, TET2). Overall, 93%
(137/148) of the samples had at least one mutation in any of these genes, whereas only 7% (11/148) showed no molecular mutation. Eight of these eleven patients without mutation had a normal karyotype, three patients carried an aberrant karyotype. This consequently leads to a combined detection rate of alterations in 140/148 (95%) of patients with CMML having cytogenetic and/or molecular genetic aberrations. 12% (18/148) showed mutations in one gene; but in none of these 18 cases did a sole mutation of either SRSF2 or RUNX1 occur.
Most of the cases had simultaneous mutations in two (33%; 49/148) or three (28%; 42/148) genes. In cases with mutations involving two genes, one of the two mutated genes was SRSF2 in 49% (24/49) of the samples. In these cases the mutational load of SRSF2mut was equal or beneath the mutational load of the second mutated gene. Four mutations occurred in 22/148 cases (15%). In only five patients mutations in five genes were observed (5/148; 3%), one patient carried mutations in seven genes (1/148; 1%).
Impact of SRSF2 mutation on clinical outcome
Follow-up data was available in 180 cases (median follow up of 12 months; median overall survival (OS): 29.6 months). This cohort comprised 117 CMML-1 (65%) and 63 CMML-2 (35%) cases, and 93 patients had mutations in SRSF2 (52%). Calculation of the OS for prognostic relevance of ASXL1, EZH2, TET2, and RUNX1 mutations in the total CMML cohort revealed an adverse impact of ASXL1mut compared to ASXL1 wild-type (wt) (median OS: 17.3 months vs. not reached (n.r.), p=0.001) and a slightly adverse impact of EZH2mut relative to EZH2wt (median OS: 18.3 vs. 29.3 months, p=0.073). TET2 and RUNX1 mutations showed no impact on OS (Supplemental Figure S5) . Finally, the influence of SRSF2 mutation on survival was analyzed. In the total cohort, no impact of SRSF2 mutations on OS was observed (Fig. 4A) . Due to the high coincidence of SRSF2 mutations with TET2 mutations and the prognostic relevance of RUNX1 and ASXL1 alterations in MDS and CMML, respectively, we additionally analyzed these specific subcohorts, resulting in no statistically significant differences. Further, the three most frequently appearing missense mutations (Pro95His, Pro95Leu, and Pro95Arg) were analyzed separately. The OS curve of Pro95His mutated cases showed a slightly better course compared to the wt SRSF2 cases, whereas the OS of Pro95Leu and Pro95Arg was slightly shorter than of the wt (see Supplemental Figure S6 ). Based on these finding, we calculated the prognostic relevance of Pro95His separately in the above mentioned 
Discussion
A number of molecular targets have been identified that are frequently mutated in MDS or MDS/MPN. Thereby, some cellular pathways became apparent that are affected by mutations of several genes, including tyrosine kinase signaling and epigenetic regulation. 5;6;8;20 Very recently, components of the splicing machinery were found to be frequently mutated in MDS, including mutations in U2AF1, ZRSR2, SF3B1, and SRSF2. 7 All of these factors are involved in 3'-splice site recognition of pre-mRNA, inducing abnormal RNA splicing.
In the present study, we analyzed 275 CMML patients for mutations in SRSF2 and found a high frequency of mutations (47%). This frequency is even higher than the 28% that is described in the primary publication of Yoshida et al. 7 This difference in frequencies may be caused by ethnic differences of the two cohorts, more stringent patient selection and diagnostic procedures (using in all cases non-specific esterase for calculation of monocytes)
or partially by methodological differences. For example the next-generation short read sequencing platform which was used in the previous study may have missed the in/del mutations. SRSF2, therefore, belongs to the most frequently mutated genes in CMML together with TET2 and ASXL1, with incidences of 61% and 44%, respectively, which is comparable to the frequencies of 44-50% 6;22 and 49% 20 in previous studies.
Of note, all other results of our mutational screening were in line with recently published data. RUNX1 was mutated in 22% of the cases, which is in the range of findings reported by Kohlmann et al., 6 and Gelsi-Boyer et al., 37 with frequencies of 9%, and 30%
respectively. Likewise, CBL was mutated in 19% of the cases; and therefore in the range of 13% and 22%, reported by Grand et al. 32 and Kohlmann et al., 6 respectively. In this paper with our enlarged cohort we also confirmed the mutation frequency of RAS gene mutations of 30%, also observed by Kohlmann et al. 6 (16% for NRAS and 11% for KRAS). Grossmann et al. 5 found a mutation frequency of 11% for EZH2, which was confirmed with 10%. Levine et al. 38 noted a mutation frequency of 8% for JAK2, which is in line with the 7% mutated cases observed in this study. IDH1/2 showed a mutation frequency of 5%, 5 being in line with 4% presented in Jankowska et al. 8 The cytogenetic risk stratification suggested by Such et al. 4 For functional insights of the SRSF2 mutations various computational analyses were performed. Since a crystal structure of SR-proteins is not available, bioinformatic tools were used to predict the character of the missense mutations and to generate SRSF2 structural models based on the AA sequence. All missense mutations of Pro95 in this study were predicted to be damaging. Recently, Daubner et al. analyzed the RNA binding mode of SRSF2 and indicated that Pro95 forms extensive contact with RNA. 39 Also the three newly described mutations with deletions and insertions are suggestive of being even more deleterious. Comparison of the calculated models indicated that the mutations affected the linker sequence. Therefore, the topography of the two domains (RRM and RS) might have changed as a result of an altered number or structure of the AA. Considering the fact that no frame-shift or nonsense mutations occurred, the protein probably retains both structural integrity and any other modified function.
SRSF2 belongs to the SR-protein family and is therefore a splicing factor involved in alternative splicing (reviewed in 25;26 ). Alternative splicing is an essential process by which eukaryotes generate high protein diversity from a single gene through the selective joining of different exons. Over 60% of human genes have been estimated to be alternatively spliced, 40 indicating that regulation of alternative splicing is an important event. Mutations in both the nucleotide sequence of splicing regulatory elements and the components of the cellular splicing machinery can result in aberrant splicing. In addition, aberrant splicing has been found to be associated with various diseases, including cancer. 45 Moreover, miss-expression of SR-proteins changes the alternative splicing pattern, and is associated with the development of cancer. Increased expression of SR-proteins correlates with cancer progression, as was shown for SRSF2 in ovarian cancers. 46 On the other hand, depletion of SRSF2 in the thymus of a mouse model changed the alternative splicing of CD45, causing a defect in T-cell maturation. 47 Lareau et al. reported that SRSF2 directs the splicing of its own transcripts and autoregulates its own expression by coupling alternative splicing with RNA decay. 48 Recent reports indicate further functions of SRSF2 in transcription, promoting RNA Pol II elongation, genome stability, and cell-cycle progression (reviewed in 25;49 Depletion of SRSF2 has been reported to trigger overwhelming double strand breaks (reviewed in 49 ).
Mutations in SRSF2 were highly associated with TET2 mutations, a protein converting The median OS of our cohort is 29.6 months, indicating that the outcome of our cohort is somehow better than in other data sets published (e.g. 3 ). This may be due to the fact that 60% of the patients sent for diagnosis to our institution are referred from outpatient units and hematologists´ practices at first suspect of CMML and thus are diagnosed very early. Many of our patients were not treated upfront but followed a watch-and-wait-strategy.
This may in part explain the differences in the survival curves in comparison to other studies published from centers to which the patients were referred in order to receive treatment Table 1 Clinical characteristics, cytogenetics, and molecular mutations of 275 CMML patients.
Parameters describing the three groups: total cohort, SRSF2mut, and SRSF2wt are listed.
Analyzed case numbers n and percentages or ranges are provided in parenthesis. p-values are given for significant differences. n.s. = not significant. 
